STOCK TITAN

Aurinia Pharmaceuticals Inc - AUPH STOCK NEWS

Welcome to our dedicated news page for Aurinia Pharmaceuticals (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aurinia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aurinia Pharmaceuticals's position in the market.

Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced that its collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) in Japan. This follows the FDA approval of voclosporin in the U.S. for the treatment of adult patients with active LN. The collaboration agreement also includes potential royalties for Aurinia upon approval in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. presented five studies at the annual American College of Rheumatology Convergence 2023, reinforcing the safety and effectiveness of LUPKYNIS® (voclosporin) for the treatment of adult patients with active lupus nephritis. The data showed improved safety and efficacy outcomes compared to conventional regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aurinia Pharmaceuticals presented nine studies at the American Society of Nephrology Kidney Week 2023 Convergence. The studies reinforced the safety and effectiveness of LUPKYNISⓇ for the treatment of adult patients with active LN. A repeat kidney biopsy sub-study showed improvement in histologic activity without chronic injury. A propensity analysis suggested that LUPKYNISⓇ plus standard of care reduced toxicities and demonstrated earlier reductions in proteinuria. Black patients experienced improved outcomes with LUPKYNISⓇ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
none
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported a net product revenue of $40.8 million for Q3 2023, a 60% increase compared to the same period last year. The total net revenue for the nine months ended September 30, 2023, was $130.4 million, a 24% increase over the prior year. The company achieved a pricing and reimbursement milestone, triggering a $10 million payment from Otsuka Pharmaceutical Co. Ltd. They have narrowed their net product revenue guidance for 2023 to a range of $155 - $160 million. The company also highlighted the full results from AURORA 2, demonstrating kidney preservation and additional efficacy of LUPKYNIS. They appointed three new directors to the Board of Directors and provided updates on LUPKYNIS product performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.52%
Tags
-
Rhea-AI Summary
Aurinia Pharmaceuticals welcomes the updated recommendations from EULAR for the management of lupus nephritis. The recommendations suggest considering LUPKYNIS as a new treatment paradigm and highlight the importance of early intervention and combination therapies. They also recommend a lower maintenance dose of steroids and vigilant monitoring for new organ damage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
Rhea-AI Summary
Aurinia Pharmaceuticals to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
Rhea-AI Summary
Aurinia Pharmaceuticals to release third quarter financial and operational results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
-
Rhea-AI Summary
Aurinia Pharmaceuticals announces data presentations at upcoming medical conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
-
Rhea-AI Summary
Aurinia Pharmaceuticals appoints Dr. Robert T. Foster to the Board and enters into a cooperation agreement with MKT Capital. Dr. Foster brings deep biotech leadership experience and will contribute to the strategic review and commercialization of LUPKYNIS. Recent governance enhancements and the initiation of a strategic review are expected to create meaningful value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
management
Rhea-AI Summary
Aurinia Pharmaceuticals appoints Dr. Karen Smith and Jeffrey A. Bailey to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
management acquisition
Aurinia Pharmaceuticals Inc

Nasdaq:AUPH

AUPH Rankings

AUPH Stock Data

723.09M
131.74M
7.45%
38.61%
8.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Victoria

About AUPH

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.